Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments
Open Access
- 5 December 2011
- journal article
- review article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 52 (Supplement) , 93S-100S
Abstract
Many factors affect standardized uptake values (SUVs) in 18F-FDG PET/CT. The use of the SUV from a single PET scan in multicenter studies requires the standardization of 18F-FDG PET/CT procedures. In the context of treatment response assessments (repeated PET scans), many factors may seem to have minor effects on percentage changes in SUVs, provided that imaging procedures are executed in a consistent manner for each subject. However, the use of 18F-FDG PET/CT in a nonstandardized manner will result in unknown biases and reproducibilities of SUVs and SUV-based response measures. This article provides an overview of the need for standardization in relation to the specific use of SUVs and SUV changes in studies of treatment response assessments.Keywords
This publication has 29 references indexed in Scilit:
- Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell Lung Cancer: Update of a Systematic Review and Meta-Analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging ProjectJournal of Thoracic Oncology, 2010
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Standards for PET Image Acquisition and Quantitative Data AnalysisJournal of Nuclear Medicine, 2009
- Recommendations on the Use of 18F-FDG PET in OncologyJournal of Nuclear Medicine, 2008
- Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancerCancer, 2007
- Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- The value of [18F]fluoro-2-deoxy-?-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatmentLung Cancer, 2003
- An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancerThe Annals of Thoracic Surgery, 2002
- Monitoring response to therapy in cancer using [ 18 F]-2-fluoro-2-deoxy- d -glucose and positron emission tomography: an overview of different analytical methodsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999